US equities |
NVDA $240.13 ▲+0.52% SPCX $172.73 ▲+0.96% MU $1,061.66 ▼-0.22% MRVL $290.19 ▲+6.98% AMD $655.58 ▲+3.77% INTC $114.67 ▼-1.31% AVGO $378.47 ▲+4.40% TSLA $380.07 ▲+0.36%
FinancialContent

Latest News about NASDAQ:UNCY

Recent news which mentions NASDAQ:UNCY

UNCY Stock Earnings: Unicycive Therapeutics Beats EPS for Q2 2024
Tickers UNCY
Tags Earnings Reports Market News UNCY
From InvestorPlace
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024
Tickers UNCY
Tags NASDAQ:UNCY Market News UNCY
From InvestorPlace
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023
Tickers UNCY
Tags NASDAQ:UNCY Earnings Reports Market News
From InvestorPlace
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
Tickers UNCY
Tags NASDAQ:UNCY
From News Direct
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
Tickers UNCY
Tags NASDAQ:UNCY
From News Direct
Unicycive: The Company Developing Key Kidney Therapies
Tickers UNCY
Tags NASDAQ:UNCY
From News Direct
Unicycive: This Biotech Company Receives Promising Results From New Trial
Tickers UNCY
Tags NASDAQ:UNCY
From News Direct
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
Tickers AKBA ARDX CARA UNCY
Tags NASDAQ:UNCY
From News Direct
Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden
Tags NASDAQ:UNCY
From News Direct
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
Tickers AKBA DVA UNCY
Tags NASDAQ:UNCY
From News Direct
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Tickers AKBA FMS LPCUF UNCY
Tags NASDAQ:UNCY
From News Direct